<code id='3169C2DA28'></code><style id='3169C2DA28'></style>
    • <acronym id='3169C2DA28'></acronym>
      <center id='3169C2DA28'><center id='3169C2DA28'><tfoot id='3169C2DA28'></tfoot></center><abbr id='3169C2DA28'><dir id='3169C2DA28'><tfoot id='3169C2DA28'></tfoot><noframes id='3169C2DA28'>

    • <optgroup id='3169C2DA28'><strike id='3169C2DA28'><sup id='3169C2DA28'></sup></strike><code id='3169C2DA28'></code></optgroup>
        1. <b id='3169C2DA28'><label id='3169C2DA28'><select id='3169C2DA28'><dt id='3169C2DA28'><span id='3169C2DA28'></span></dt></select></label></b><u id='3169C2DA28'></u>
          <i id='3169C2DA28'><strike id='3169C2DA28'><tt id='3169C2DA28'><pre id='3169C2DA28'></pre></tt></strike></i>

          focus

          focus

          author:comprehensive    Page View:2
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more
          Key Senate panel to consider PBM, drug pricing reform package
          Key Senate panel to consider PBM, drug pricing reform package

          Sens.RonWydenandMikeCrapointroducedamentalhealth,PBMreformandsubstanceusepolicypackage.DrewAngerer/G

          read more
          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more

          Inari Medical to buy amputation prevention company LimFlow

          Inariwillpay$250millionupfrontand$165moredependingonLimFlow’scommercialsuccess.DavidGregory&Debb